Pages that link to "Q67172860"
Jump to navigation
Jump to search
The following pages link to Mark Pimentel (Q67172860):
Displaying 50 items.
- Identification of a prodromal period in Crohn's disease but not ulcerative colitis (Q22242350) (← links)
- Measuring response in the gastrointestinal tract in systemic sclerosis (Q27022416) (← links)
- Biomarkers of Irritable Bowel Syndrome (Q28069902) (← links)
- Rifaximin Therapy for Patients with Irritable Bowel Syndrome without Constipation (Q28302405) (← links)
- Risk of inflammatory bowel disease following a diagnosis of irritable bowel syndrome (Q31062841) (← links)
- Methane and the gastrointestinal tract (Q33443954) (← links)
- Gastrointestinal bacterial overgrowth: pathogenesis and clinical significance (Q33459081) (← links)
- Placebo effect in clinical trial design for irritable bowel syndrome (Q33586880) (← links)
- The Treatment of Patients With Irritable Bowel Syndrome: Review of the Latest Data From the 2010 DDW Meeting (Q33688135) (← links)
- Psychological disorders in gastrointestinal disease: epiphenomenon, cause or consequence? (Q33813422) (← links)
- Inflammation and Microflora (Q33824492) (← links)
- Low-dose nocturnal tegaserod or erythromycin delays symptom recurrence after treatment of irritable bowel syndrome based on presumed bacterial overgrowth. (Q33916182) (← links)
- Abnormal breath testing in IBS: a meta-analysis (Q34115362) (← links)
- The prevalence of overgrowth by aerobic bacteria in the small intestine by small bowel culture: relationship with irritable bowel syndrome (Q34248518) (← links)
- Autoimmunity Links Vinculin to the Pathophysiology of Chronic Functional Bowel Changes Following Campylobacter jejuni Infection in a Rat Model (Q34449503) (← links)
- Increased prevalence of irritable bowel syndrome in patients with gastroesophageal reflux (Q34548906) (← links)
- The effect of a nonabsorbed oral antibiotic (rifaximin) on the symptoms of the irritable bowel syndrome: a randomized trial (Q34574085) (← links)
- Studying the overlap between IBS and GERD: a systematic review of the literature (Q34578629) (← links)
- Rifaximin versus other antibiotics in the primary treatment and retreatment of bacterial overgrowth in IBS. (Q34579745) (← links)
- A systematic review of diagnostic tests for small intestinal bacterial overgrowth (Q34584713) (← links)
- Pathogen-specific risk of chronic gastrointestinal disorders following bacterial causes of foodborne illness (Q34627613) (← links)
- Antibiotics for irritable bowel syndrome: rationale and current evidence (Q34642080) (← links)
- Healthy control subjects are poorly defined in case-control studies of irritable bowel syndrome (Q34907508) (← links)
- Case studies of antibiotic therapy in the management of functional gastrointestinal disorders. (Q34985950) (← links)
- Apple sauce improves detection of esophageal motor dysfunction during high-resolution manometry evaluation of dysphagia (Q34990573) (← links)
- Gas and the microbiome (Q35024458) (← links)
- Development and validation of a biomarker for diarrhea-predominant irritable bowel syndrome in human subjects (Q35603014) (← links)
- A 14-day elemental diet is highly effective in normalizing the lactulose breath test (Q35678957) (← links)
- Antibiotics for the treatment of irritable bowel syndrome (Q35691133) (← links)
- Intestinal methane production in obese individuals is associated with a higher body mass index (Q35749939) (← links)
- Breath Testing for Small Intestinal Bacterial Overgrowth: Should We Bother? (Q35931566) (← links)
- Small intestinal bacterial overgrowth is associated with irritable bowel syndrome and is independent of proton pump inhibitor usage (Q36073385) (← links)
- Measurement of gastrointestinal transit (Q36178630) (← links)
- Bacteria and irritable bowel syndrome: the evidence for small intestinal bacterial overgrowth (Q36534298) (← links)
- Visceroptosis of the bowel in the hypermobility type of Ehlers-Danlos syndrome: presentation of a rare manifestation and review of the literature (Q36599319) (← links)
- Metabolic effects of eradicating breath methane using antibiotics in prediabetic subjects with obesity (Q36625912) (← links)
- Bacterial concepts in irritable bowel syndrome (Q36916612) (← links)
- Irritable Bowel Syndrome: Bacterial Overgrowth--What's Known and What to Do. (Q36924485) (← links)
- A combination of rifaximin and neomycin is most effective in treating irritable bowel syndrome patients with methane on lactulose breath test (Q37649460) (← links)
- Lactose intolerance and the role of the lactose breath test (Q37777958) (← links)
- Irritable Bowel Syndrome and Small Intestinal Bacterial Overgrowth (Q37788512) (← links)
- Methane on Breath Testing Is Associated with Constipation: A Systematic Review and Meta-analysis (Q37834415) (← links)
- Effects of Rifaximin Treatment and Retreatment in Nonconstipated IBS Subjects (Q37874146) (← links)
- Evaluation of harm in the pharmacotherapy of irritable bowel syndrome (Q37996566) (← links)
- Identifying and testing candidate genetic polymorphisms in irritable bowel syndrome: association with TNFSF15 and tumor necrosis factor-α (Q38357737) (← links)
- Serum sTREM-1 as a surrogate marker of treatment outcome in patients with peptic ulcer disease (Q38490148) (← links)
- Evaluation of peripapillary lymphocytosis and lymphocytic esophagitis in adult inflammatory bowel disease (Q38676151) (← links)
- How to Test and Treat Small Intestinal Bacterial Overgrowth: an Evidence-Based Approach (Q38701265) (← links)
- "Pre-cebo": an unrecognized issue in the interpretation of adequate relief during irritable bowel syndrome drug trials (Q39245759) (← links)
- Importance of Diarrhea in Evaluating Constipation in Irritable Bowel Syndrome Clinical Studies (Q39785351) (← links)